Drug main Lupin on Wednesday introduced the launch of its Favipiravir drug underneath the model identify “Covihalt” for the therapy sufferers with gentle to average COVID-19 signs at Rs 49 per pill in India.
Favipiravir has obtained authorisation from the Drug Controller Normal of India (DCGI) for emergency use, Lupin mentioned in a regulatory submitting.
Its Covihalt dosage energy has been developed conserving in thoughts comfort of administration, it said, including that the drug is accessible as 200 mg tablets within the type of a strip of 10 tablets, and priced at Rs 49 per pill.
Lupin President – India Area Formulations (IRF) Rajeev Sibal mentioned the corporate believes that it could possibly leverage its experience in managing widespread group ailments like tuberculosis to proactively attain sufferers throughout India and guarantee entry to Covihalt by its sturdy distribution community and area drive.
On August 4, Solar Pharmaceutical Industries had launched Favipiravir underneath the model identify “FluGuard” for the therapy of gentle to average circumstances of COVID-19, at Rs 35 per pill in India.
Shares of Lupin had been buying and selling 0.32 per cent greater at Rs 943.70 apiece on BSE.
(This story has not been edited by NDTV employees and is auto-generated from a syndicated feed.)